Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment - Wikidata - wikimedia - TriplyDB

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

http://www.wikidata.org/entity/Q36190723

about

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control Enhancing Cancer Immunotherapy Via Activation of Innate Immunity NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Ly49 receptors: innate and adaptive immune paradigms HDAC inhibitors and immunotherapy; a double edged sword?Advantages and clinical applications of natural killer cells in cancer immunotherapy Current perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptors Carbohydrate-mimetic peptides for pan anti-tumor responses Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation Cutting edge: Ly49C/I⁻ neonatal NK cells predispose newborns to autoimmune ovarian disease induced by maternal autoantibody.The unique neonatal NK cells: a critical component required for neonatal autoimmune disease induction by maternal autoantibody Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy Human CD56dimCD16dim Cells As an Individualized Natural Killer Cell Subset.Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective GD2-targeted immunotherapy and radioimmunotherapy CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells Neuroblastoma: developmental biology, cancer genomics and immunotherapy.Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8 Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment.Tumor-Associated Glycans and Immune Surveillance Polyclonal Expansion of NKG2C(+) NK Cells in TAP-Deficient Patients Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Murine natural killer cell licensing and regulation by T regulatory cells in viral responses.Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice Natural killer cell licensing in mice with inducible expression of MHC class I.A new tumorsphere culture condition restores potentials of self-renewal and metastasis of primary neuroblastoma in a mouse neuroblastoma model.Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry

P2860

Q21131216-70D744AD-4B6C-40D1-906E-75C4D6FDC34C Q26747397-4B3D245C-1353-4938-BF36-5F1DD5000757 Q26796313-C8DEDCE7-4FB2-44E6-A8DD-DD94EEAE6061 Q26797345-0E017AF7-FC83-4850-8936-61AEA4F6E4B3 Q26825078-B527F8F5-D540-4D4E-A6DB-7FE2793E8D9C Q26853102-928E4654-C36C-44A6-BA4B-0275E5B07AA7 Q26999224-3BFFC613-6D00-4A89-BF71-44BB84602E38 Q27009135-34DF7CAF-FA95-420E-8044-02892200FAC6 Q27023624-EBE7A451-935C-492E-8DBE-B2A8DD74EA4F Q28069682-9DC46FB9-436C-4770-9BF4-64ED15A27C95 Q30410722-E2403AE0-7B90-4706-8058-0CEDFE431580 Q30412615-A7960A37-4419-464D-919E-5BC61F618486 Q30916013-6267A352-BB19-4CBA-B3DB-C243995CFFF3 Q33740971-CD1C3BE7-9C0A-4BCD-B064-7194B73AA204 Q33785744-D03D3BF8-3067-49BE-A631-D0ECF3CD4931 Q33810001-889A39BB-E751-4024-B22C-6D8200DE56A4 Q33816097-87EDA5B1-2C91-4769-974B-A62741A891A8 Q34180695-34BD64A0-ACE9-45E0-B84E-B672945F8DF1 Q34625339-7265D8EE-55C4-46F2-B7DC-F7F53B5241C6 Q34688644-F42E7904-8FDA-429D-8BFC-E651A59C3EE9 Q34939364-1236BCA4-7AD5-4D59-80DD-3649E1BAA978 Q34992670-ADB97C99-2BE1-4FBC-B8A1-BD426366D5B2 Q35283020-885534F3-2C70-416E-A49F-3E3B5B1CBAFC Q35799180-E88A23C2-A83B-4C7E-8C3A-FAF498A3F628 Q35860917-9C004855-583F-46C5-88E9-C6585FF1BB7D Q35887296-8CCCCC25-D973-48D6-BA5E-A16A18A35C3E Q35890610-69AFA229-0F1D-4C37-AD12-E2C345F3F152 Q36123419-D1688BCC-C388-4BC9-851E-538C62D1B1AD Q36444198-4453EACB-DBF1-4BBB-8045-0D8425894687 Q36544773-A9E66D69-322C-4E90-B20C-37F783E01643 Q36782374-A42B41C1-D6F1-4535-9194-6549839874CF Q36820198-07A5FC0F-AA56-4383-A3F8-BB27362842E4 Q36856792-6E736DE2-B502-4A59-8DE1-54AD3E22BD20 Q37078946-08CA5621-1973-4F44-8B1E-2C7B786197E2 Q37130228-93C3510B-7D38-4D01-8518-82836E3B7F8E Q37222176-CE93F3D5-EB70-46E3-922D-1FC301703D56 Q37318105-3A377449-7D4C-4A17-91E7-C2B730D5BCC5 Q37505981-237A56B1-1926-49DB-B0B4-F2CA5773B618 Q37535232-5846641A-FA91-4DD9-A452-882EFD8E5286 Q37569278-33AD1244-2D65-4E51-8784-6BD0ACF1E171

P2860

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

http://www.wikidata.org/entity/Q36190723

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

@ast

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

@en

type

label

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

@ast

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

@en

prefLabel

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

@ast

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

@en

P1433

Q36190723-96B683A1-A0B5-45E9-B571-93C462417101

P1476

Q36190723-117E2313-F6EF-4D99-B7FE-A5C85C005C27

P2093

Q36190723-00469D48-61F4-4B64-AAB7-5C1D161DCA74

Q36190723-0F47C250-1AAB-4842-8116-2E0E4CC7A99D

Q36190723-4F084876-8210-42C3-A5BB-32E67A2E3228

Q36190723-7A4AFFCA-C2FA-456B-A1C1-A64B48DA4C89

Q36190723-B74668AE-DC63-4F67-A07A-2732BD0276E7

Q36190723-B88AF640-D65E-483A-8945-74B2DA981E5F

Q36190723-C1CE3229-0D71-4D2A-AD9B-CA8EC053D60E

Q36190723-C3873D38-0C35-47CD-822F-E32726BF69CA

Q36190723-E858B9C1-2F49-4C05-92CD-2C7857726542

P2860

Q36190723-00D5E2B6-3138-4FEB-85F0-72309FBB1110

Q36190723-0D12B56D-5AA1-463A-8FD1-8D8C97C60798

Q36190723-101BF243-99A6-484D-9676-89F2FA549A72

Q36190723-1071FA85-4EA1-416E-9F48-20F0400AAED6

Q36190723-1C4D7A04-06AE-412F-9992-51365EEA3535

Q36190723-1CD0DCAB-B749-49D3-85EB-63E0808C2EF9

Q36190723-2289EFEA-AE2F-4DF1-8290-143412105CAC

Q36190723-22A46153-9339-419B-BBF4-AE149886EACE

Q36190723-23B9CA55-0B5E-4238-B81B-D73988E1D48F

Q36190723-29AE5F16-7D65-45D0-B33C-FB412CC77273

P304

Q36190723-21A8631F-ECBF-40FB-A3AC-96CB94972B1A

P31

Q36190723-0967EB65-2249-4198-B311-A9B962D7702C

P356

Q36190723-2CAE403E-006E-45FA-8285-D8463A8D95BD

P407

Q36190723-37489B1E-2BF6-46E0-8761-D87F9555C9A2

P433

Q36190723-3B91B118-2D4B-4459-A27C-EEA0C543B949

P478

Q36190723-95696A1F-EED5-4663-8037-36AAA73D953C

P50

Q36190723-11EAB933-8388-431F-A0C6-1B07DF75DAC4

Q36190723-5490FAA1-E384-436C-A1DF-873DC9FADC65

P577

Q36190723-EA244424-DAB0-4030-B0F7-4697E1455D44

P698

Q36190723-0611AA38-2560-47CF-8E6E-CEB7BDDFBC50

P921

Q36190723-13594272-D527-4AD2-B94C-B76B351A8FA9

P932

Q36190723-6492C95E-1676-4D2E-BFCB-C39752043EC5

P356

P1433

Journal of Clinical Investigation

P1476

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

@en

P2093

Elizabeth Chamberlain

http://www.w3.org/2001/XMLSchema#string

Glenn Heller

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Venstrom

http://www.w3.org/2001/XMLSchema#string

Junting Zheng

http://www.w3.org/2001/XMLSchema#string

Katharine C Hsu

http://www.w3.org/2001/XMLSchema#string

Meighan M Gallagher

http://www.w3.org/2001/XMLSchema#string

Nai-Kong V Cheung

http://www.w3.org/2001/XMLSchema#string

Nidale Tarek

http://www.w3.org/2001/XMLSchema#string

Shakeel Modak

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Rituximab: mechanism of action

Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.

Functions of natural killer cells

NK cell recognition

NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets.

The biology of human natural killer-cell subsets.

P304

3260-3270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI62749

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Benoit Le Luduec

P577

2012-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22863621

http://www.w3.org/2001/XMLSchema#string

P921

P932

3428088

http://www.w3.org/2001/XMLSchema#string